Ronald Bennett, MD
Internal Medicine · Franklin, INNPI 1740284470
Payments from drug & device makers
Across 85 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$241
- Novo Nordisk$195
- AstraZeneca$121
- Sanofi$88
- Exact Sciences$87
- Abbott$69
- plus $403 from 19 others
What the payments were for
- Food & beverage$1,204100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 21 | $241 |
| Novo Nordisk | 17 | $195 |
| AstraZeneca | 5 | $121 |
| Sanofi | 5 | $88 |
| Exact Sciences | 5 | $87 |
| Abbott | 4 | $69 |
| Pfizer | 5 | $65 |
| Astellas Pharma US Inc | 3 | $45 |
| Sanofi Pasteur Inc. | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Merck | 2 | $24 |
| Nalpropion Pharmaceuticals LLC | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Medtronic | 1 | $15 |
| AbbVie | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Biogen | 1 | $11 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$1,204 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $91,089 |
| EliquisApixaban | 71 | $80,215 |
| JardianceEmpagliflozin | 48 | $64,169 |
| JanuviaSitagliptin Phosphate | 48 | $55,907 |
| MounjaroTirzepatide | 35 | $50,516 |
| XareltoRivaroxaban | 11 | $20,367 |
| LinzessLinaclotide | 20 | $20,335 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $19,734 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 69 | $15,293 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $14,206 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $11,319 |
| Spiriva RespimatTiotropium Bromide | 11 | $7,841 |
| MyrbetriqMirabegron | 11 | $6,120 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,394 |
| Atorvastatin Calcium | 474 | $4,447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $195 | $91,08984 claims |
| PfizerEliquis | $65 | $80,21571 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $12 | $72,01059 claims |
| MerckJanuvia, Janumet Xr | $24 | $67,22665 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta | $241 | $54,628117 claims |
| AbbVieLinzess, Synthroid | $15 | $22,93875 claims |
| Johnson & JohnsonXarelto | $13 | $20,36711 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $6,12011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Franklin
- George CornettFranklin$1.3M
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.